International circulation:First， I’d like to thank you， Doctor Anker for joining international circulation here at the 2009 AHA scientific sessions. At this session， just now we saw the presentation of several trials on heart failure. We would pacifically be interested first perhaps in the heal trial. We saw some interesting results presented here on the heal trials. And perhaps you can give us your view on we’ve seen some of these results? What is the role of this trial in the field of heart failure? What is your preliminary view on these results?

     《国际循环》：在这次年会上，刚刚我们看到几个心衰试验的报告。首先我们对HEAAL试验尤其感兴趣。我们看到HEAAL试验有些有趣的结果。或许您能就我们看到的结果谈谈您的看法？该试验在心衰领域的作用是什么?您对这些结果有什么初步看法？

    Anker: Thank you very much for having me. What’ve seen here today is quite momentous session. There hasn’t been such successful collection of heart failure trials in the past 5 or 7 years. When one session out of 4 studies，3 heart failure trials are very successful and amongst them， also one of them， was as you said， the Heal study. There was also a very successful trial， investigating left ventricular assist devices， the heart rate two clinical trial destination study， and a fair jeff trial investing intravenous iron patient with heart failure and iron deficiency. Now specifically for the heal study， that study investigated in patients with systolic heart failure with neuro class two to four. The utility of giving them 50 milligrams or 150 milligrams of Losatram which is an androgen receptor antagonist， the patients had to be intolerant to ACE inhibitor. And then we will randomize into the studies in one of the two treatment arms  Now， when it comes to this study and it’s overall meaning one needs to see this in the context of previous studies. Like the early two trials for instance， where Losartan with 50 milligrams was compared to Captopril， and when taking this study， and the results seen here today we can conclude basically that a higher dose of Losartan is better than lower dose with regards to outcomes for heart failure patients.

    Anker教授：非常感谢你的采访。我们今天看到的年会非常有意义。在过去的5年或7年中没有这么多成功的心衰试验了。在一次年会中的4个研究中，3个心衰试验非常成功，其中一个是你提到的HEAAL试验。还有个很成功的试验，研究左心室辅助装置和心率有两个临床试验终点的研究，以及关于心衰合并铁缺乏的患者静脉注射铁剂的FAIR–HF试验。其是HEAAL试验研究，该研究研究了心衰等级II~IV级的收缩性心衰病人。给予不耐受血管紧张素转换酶（ACE）抑制剂的患者50 mg或者150 mg的氯沙坦（血管紧张素受体拮抗剂），然后随机分组，接受其中的一种治疗。就该研究而言，它的总的意义就是要在以前研究的背景下看待该研究。比如象以前的两个试验，比较50 mg的氯沙坦与卡托普利的疗效，而就该研究我们今天看到的结果而言，我们基本可以推断，高剂量的氯沙坦比低剂量的氯沙坦在心衰患者的预后方面疗效要好。